Clostridium difficile colitis in an immunocompromised patient treated with fidaxomicin

Marcello Feasi

DOI: https://doi.org/10.7175/cmi.v9i1S.1039

Abstract

The incidence of C. difficile-associated colitis has significantly increased in recent years in hospitals and long-term healthcare facilities. It has a great impact on morbidity and mortality, particularly in high-risk patients (e.g. elderly and subjects with comorbidities or immunosuppression), who frequently have severe or recurrent infections and sometimes do not respond to conventional therapy with metronidazole or vancomycin. Fidaxomicin, recently approved in clinical use, is a new option for the treatment of C. difficile infections.

A 65-year-old woman with cryptogenetic decompensated cirrhosis underwent orthotopic liver transplantation and started immunosuppressive therapy. She had a prolonged hospitalization of nine months after transplantation with several infectious complications and numerous episodes of severe C. difficile-associated colitis. Metronidazole and vancomycin were not completely effective. Fidaxomicin showed a sustained clinical cure without other recurrence.

Keywords

C. difficile; Immunocompromised patient; Fidaxomicin

Full Text

HTML PDF

References

  • Ricciardi R, Rothenberger DA, Madoff RD, et al. Increasing prevalence and severity of Clostridium difficile colitis in hospitalized patients in the United States. Arch Surg 2007; 142: 624-31; http://dx.doi.org/10.1001/archsurg.142.7.624
  • DuPont HL, Garey K, Caeiro JP, et al. New advances in Clostridium difficile infection: changing epidemiology, diagnosis, treatment and control. Curr Opin Infect Dis 2008; 21: 500-7; http://dx.doi.org/10.1097/QCO.0b013e32830f9397
  • Jones AM, Kuijper EJ, Wilcox MH. Clostridium difficile: a European perspective. J Infect 2013; 66: 115-28; http://dx.doi.org/10.1016/j.jinf.2012.10.019
  • Fekety R, McFarland LV, Surawicz CM, et al. Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial. Clin Infect Dis 1997; 24: 324-38; http://dx.doi.org/10.1093/clinids/24.3.324
  • Johnson S. Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes. J Infect 2009; 58: 403-10; http://dx.doi.org/10.1016/j.jinf.2009.03.010
  • Garey KW, Sethi S, Yadav Y, et al. Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. J Hosp Infect 2008; 70: 298-304; http://dx.doi.org/10.1016/j.jhin.2008.08.012
  • Jung KS, Park JJ, Chon YE, et al. Risk factors for treatment failure and recurrence after metronidazole treatment for Clostridium difficile-associated diarrhea. Gut Liver 2010; 4: 332-7; http://dx.doi.org/10.5009/gnl.2010.4.3.332
  • Lancaster JW, Matthews SJ. Fidaxomicin: the newest addition to the armamentarium against Clostridium difficile infections. Clin Ther 2012; 34: 1-10; http://dx.doi.org/10.1016/j.clinthera.2011.12.003
  • Kim JW. Risk factors for delayed recurrence of Clostridium difficile infection. Intestinal Res 2014; 12: 266-7; http://dx.doi.org/10.5217/ir.2014.12.4.266
  • Lim SK, Stuart RL, Mackin KE, et al. Emergence of a ribotype 244 strain of Clostridium difficile associated with severe disease and related to the epidemic ribotype 027 strain. Clin Infect Dis 2014; 58: 1723-30; http://dx.doi.org/10.1093/cid/ciu203
  • Zar FA, Bakkanagari SR, Moorthi KM, et al. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007; 45: 302-7; http://dx.doi.org/10.1086/519265
  • Clutter DS, Dubrovskaya Y, Merl MY, et al. Fidaxomicin versus conventional antimicrobial therapy in 59 recipients of solid organ and hematopoietic stem cell transplantation with Clostridium difficile-associated diarrhea. Antimicrob Agents Chemother 2013; 57: 4501-5; http://dx.doi.org/10.1128/AAC.01120-13
  • Spadao F, Gerhardt J, Guimaraes T. Incidence of diarrhea by Clostridium difficile in haematologic patients and hematopoietic stem cell transplantation patients: risk factors for severe forms and death. Rev Inst Med Trop Sao Paulo 2014; 56: 325-31; http://dx.doi.org/10.1590/S0036-46652014000400010
  • Louie TJ, Miller MA, Mullane KM, et al. OPT-80-003 Clinical Study Group. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011; 364: 422-31; http://dx.doi.org/10.1056/NEJMoa0910812
  • Scott LJ. Fidaxomicin: a review of its use in patients with Clostridium difficile infection. Drugs 2013; 73: 1733-47; http://dx.doi.org/10.1007/s40265-013-0134-z
  • Cornely OA, Crook DW, Esposito R, et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis 2012; 12: 281-9; http://dx.doi.org/10.1016/S1473-3099(11)70374-7
  • Debast SB, Bauer MP, Kuijper EJ; European Society of Clinical Microbiology and Infectious Diseases. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect 2014; 20 Suppl 2: 1-26; http://dx.doi.org/10.1111/1469-0691.12418
  • Khanna S, Pardi DS. Clostridium difficile infection: management strategies for a difficult disease. Ther Adv Gastroenterol 2014; 7: 72-86; http://dx.doi.org/10.1177/1756283X135085191 Fidaxomicina è disponibile in Italia da novembre 2013

Statistics

Abstract: 1845 views
HTML: 954 views
PDF: 261 views

Refbacks

  • There are currently no refbacks.




© SEEd srl